Comparison of citation rates between Covid-19 and non-Covid-19 articles across 24 major scientific journals.

Covid-19 has been front and center in the global landscape since the beginning of 2020. In response, the scientific field has dedicated enormous amounts of resources to researching the virus and its effects. The number of times Covid-19 publications are being cited throughout the literature appears remarkably high but has not been directly compared to non-Covid-19 papers in the same journals over an extended period. In our study, we use Clarivate's Web of Science-Science Citation Index Expanded™ database to identify Covid-19 papers published in 24 major scientific journals over a period of 24 months from January 1, 2020 to December 31, 2021. We conduct our search using keywords "Covid-19", "coronavirus", and "sars-cov-2" to locate publications with these words in the title. We then quantify the number of citations these papers have received and compare rates to non-Covid-19 papers in the same journals over the same timeframe. We find that, across 24 open-access and subscription-based scientific journals, Covid-19 papers published in the past 2 years currently have a median citation rate of 120.79 compared to 21.63 for non-Covid-19 papers. When negative binomial regression is used to minimize the influence of other variables such as article number variation and field of research, Covid-19 papers have still experienced more than 80% increase in citations relative to non-Covid-19 papers. These novel findings demonstrate that Covid-19 papers are being cited at remarkably higher rates than non-Covid-19 articles contained within the same journals. This suggests that journal impact factor, which is a product of the number of citations that recently published articles receive, will likely be drastically influenced by the number of Covid-19 papers that a journal has included within its pages in the previous years.

Intracranial microhemorrhages in the setting of COVID-19: what we know so far.

BACKGROUND: Diffuse intracranial susceptibility abnormalities have recently been described among patients with coronavirus disease 2019 (COVID-19), although prior studies have consisted of case reports and/or series. This brief literature review seeks to compile and catalogue the available data to elucidate characteristic features of such findings. MATERIALS AND METHODS: Scientific articles and studies on intracranial microhemorrhages in the setting of COVID-19 were searched on PubMed, Google Scholar, and the Cochrane Library. Included studies described intracranial microbleed(s) on magnetic resonance imaging in patients with COVID-19. If multiple patients were described, only patients with intracranial microhemorrhage on magnetic resonance imaging were included for analysis. Patient demographics, severity of illness (e.g. intensive care unit admission and/or intubation), time from diagnosis of COVID-19 to magnetic resonance imaging, and location(s) of any observed microhemorrhages were noted. RESULTS: A total of 39 patients with suspected intracranial microhemorrhages have been described in prior studies. The average age of patients was 64.7 years; 21.9% were women. The average time between COVID-19 diagnosis and magnetic resonance imaging was 31.7 days. All patients in the cohort were admitted to critical care and were either intubated or treated with extracorporeal membrane oxygenation during their clinical course. Microhemorrhages were most commonly located in the subcortical/juxtacortical white matter and corpus callosum. CONCLUSIONS: Intracranial microbleeds are a well-documented finding in patients with severe COVID-19, and are most commonly callosal and subcortical/juxtacortical in location.

COVID-19 Imaging: What We Know Now and What Remains Unknown.

Infection with SARS-CoV-2 ranges from an asymptomatic condition to a severe and sometimes fatal disease, with mortality most frequently being the result of acute lung injury. The role of imaging has evolved during the pandemic, with CT initially being an alternative and possibly superior testing method compared with reverse transcriptase-polymerase chain reaction (RT-PCR) testing and evolving to having a more limited role based on specific indications. Several classification and reporting schemes were developed for chest imaging early during the pandemic for patients suspected of having COVID-19 to aid in triage when the availability of RT-PCR testing was limited and its level of performance was unclear. Interobserver agreement for categories with findings typical of COVID-19 and those suggesting an alternative diagnosis is high across multiple studies. Furthermore, some studies looking at the extent of lung involvement on chest radiographs and CT images showed correlations with critical illness and a need for mechanical ventilation. In addition to pulmonary manifestations, cardiovascular complications such as thromboembolism and myocarditis have been ascribed to COVID-19, sometimes contributing to neurologic and abdominal manifestations. Finally, artificial intelligence has shown promise for use in determining both the diagnosis and prognosis of COVID-19 pneumonia with respect to both radiography and CT.

Coronavirus Disease 2019 and the Cerebrovascular-Cardiovascular Systems: What Do We Know So Far?

The severe acute respiratory syndrome coronavirus 2 pandemic of 2019 to 2020 has resulted in multiple hospitalizations, deaths, and economic hardships worldwide. Although respiratory involvement in patients with coronavirus disease 2019 (COVID-19) is well known, the potential cardiovascular and cerebrovascular manifestations are less understood. We performed a PubMed and Google Scholar search and reviewed relevant literature on COVID-19 and cardiovascular system involvement. Severe acute respiratory syndrome coronavirus 2 possesses high affinity for angiotensin-converting enzyme 2 receptor, which is highly concentrated in the lungs and cardiovascular tissue, thereby provoking concern for cardiovascular involvement in COVID-19 cases. Preexisting cardiovascular and cerebrovascular disease has been shown in previous reports to be a risk factor for severe infection. On the basis of our review of published studies, COVID-19 patients may be more likely to experience acute cardiac injury, arrhythmia, coagulation defects, and acute stroke and are likely to have poorer outcomes as a result. As the COVID-19 pandemic continues, more data about potential cardiovascular and cerebrovascular manifestations of the disease are required.